We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Team of the Headache and Neurological Pain group of VHIR that led the studies.
Dr. Patricia Pozo-Rosich and a patient.
Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.
In recent years, several specific drugs have been approved for the prevention of migraine. Even so, at the first symptoms of migraine, non-specific medications are still prescribed. They have not been designed for migraine and have little efficacy. Two international studies led by the Headache and Neurological Pain group at Vall d'Hebron Research Institute (VHIR) show that early administration of specific drugs to prevent migraine improves the response to therapy and can prevent disease progression. The results have been recently published in the journals JAMA Neurology and Journal of Neurology, Neurosurgery and Psychiatry.
Among the drugs designed specifically for the treatment of migraine, noteworthy are those aimed at blocking the CGRP protein, which is related to the pain associated with the pathology. These include erenumab, the first drug in this group to commercialize.
To assess the benefits of specific medication against migraine, the first of the studies, published in JAMA Neurology, analyzed the evolution of 621 patients with episodic migraine, i.e., who had less than 15 days of migraine per month. The work consisted of a phase IV clinical trial involving 84 centers in 17 countries. The patients were classified into two groups: one group received the drug erenumab and the other received non-specific medications to prevent migraine, such as beta-blockers, antiepileptic drugs, antidepressants, etc.
The researchers observed that the patients receiving erenumab responded better to treatment. In fact, the study shows that, if a patient receives erenumab, they are up to 13 times more likely to have a clinically relevant improvement after one year compared to if they receive non-specific treatment.
This study also sought to simulate clinical practice and allowed neurologists to change the treatment of patients when necessary. In this sense, patients receiving erenumab maintained the treatment more frequently than those initially receiving nonspecifics. They also had fewer side effects. "Erenumab proves to be more effective and tolerable and also significantly improves patients' adherence to treatment", explains Dr. Patricia Pozo-Rosich, head of Section of the Neurology Service and Headache Unit at Vall d'Hebron University Hospital, head of the Headache and Neurological Pain group at VHIR and director of the Migraine Adaptive Brain Center at Vall d'Hebron.
In relation to the evolution of the disease, taking the specific treatment in early stages can prevent the development of chronic migraine, in which patients have more than 15 migraine days per month. "When you start treatment late, it's much harder to reverse. If we do early treatments, we can decrease chronification. Therefore, it would be advisable to prescribe them as the first line to prevent chronic migraine and improve the quality of patients, reduce disability and reduce the associated socioeconomic costs", Dr. Pozo-Rosich emphasizes.
Despite the revolution that anti-CGRP drugs have meant for migraine therapy, there is still a large percentage of people who do not achieve clinical improvement. Vall d'Hebron has led a study, published in the Journal of Neurology, Neurosurgery and Psychiatry, to investigate which variables influence the response to therapy. The work, carried out in nearly 6,000 people from 35 centers and 7 European countries, analyzed the factors that influence response to anti-CGRP therapies. It is a real-life study with patients who had previously received non-specific drugs and had no response, and who at the time of the study were taking anti-CGRP drugs, such as erenumab, among others.
Key factors favoring response to therapy included having fewer migraines per month or less disease-associated disability. "The results underline the importance of starting treatment early to improve the evolution of the disease, without waiting for other non-specific drugs to be ineffective", says Dr. Edoardo Caronna, neurologist at the Headache Unit of the Vall d'Hebron University Hospital and principal investigator of the Headache and Neurological Pain group at VHIR.
On the other hand, the team observed that there were other factors associated with a better response to treatment, such as having pain on only one side of the head or not suffering from depression. In addition, although the sex of the person did not influence the response, a better response was observed in older people.
“All these factors help us understand why some patients respond or not, but we need to continue research to have specific biomarkers for the diagnosis, follow-up, and response to migraine treatment that will allow us to identify people who will respond to therapy before taking it", concludes Dr. Pozo-Rosich, who assures that personalized medicine will help achieve a better quality of life in patients with this neurological disease that can be very disabling.
Specific medication is more effective than non-specific treatments in preventing migraine symptoms, improving the quality of life of patients and even reducing disability and avoiding chronification.
Neurology, General Hospital
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.